Medical devices — US PTAB Patent Cases
376 decisions indexed
Page 3 of 13 · 376 total
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that all nine claims of Inari Medical’s hemostasis‑valve patent are unpatentable, finding anticipation and obviousness over Schaffer, Hartley, Eller and Garrison references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB granted institution of an IPR on Inari Medical’s 12,109,384 patent covering hemostasis valves. All nine claims are under review based on anticipation and obviousness arguments centered on the Schaffer reference and related prior art.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB granted institution of an IPR against Inari Medical’s 11,969,333 patent covering intravascular clot‑removal systems. Petitioner Imperative Care showed a reasonable likelihood of success on at least one claim, prompting the Board to institute review on all challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success on at least one claim.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The USPTO denied Imperative Care’s petition for inter partes review of Inari Medical’s patent, finding no reasonable likelihood of success. The decision was based on discretionary review under 35 U.S.C. § 314(a).
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,865,291 B2 hemostasis valve patent after Imperative Care showed a reasonable likelihood of success. All 16 challenged claims are now subject to trial.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s 11,974,910 patent covering clot‑removal systems. Imperative Care successfully demonstrated a reasonable likelihood of unpatentability on multiple claims, prompting full‑scale review.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,844,921 B2 hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success on at least one claim. The dispute centers on the definition of “filament” and the applicability of Schaffer, Hartley, and Eller references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted inter partes review on all fifteen claims of Inari Medical’s ’005 patent, finding Imperative Care’s obviousness arguments against the hemostasis valve features sufficiently plausible.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that Imperative Care’s challenge to Inari Medical’s hemostasis valve patent succeeded, finding all nine claims unpatentable under §§ 102 and 103 based on prior‑art references Schaffer, Hartley, Eller, and Garrison.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted inter partes review of Inari Medical’s 11,844,921 B2 hemostasis valve patent after finding Imperative Care has shown a reasonable likelihood of success on at least one claim. The dispute centers on whether the claimed “filament” must be flexible, with the Board presently favoring the patent owner’s interpretation.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 B2 embolism‑treatment patent after finding Imperative Care likely to prevail on at least one claim. All 15 claims are now under review.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care’s petition to invalidate Inari Medical’s hemostasis valve patent was granted. The Board found a reasonable likelihood of success on anticipation and obviousness grounds and instituted review of all nine claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s hemostasis valve patent (U.S. Patent 11,697,012) on all nine claims after finding the challenger, Imperative Care, showed a reasonable likelihood of prevailing. The dispute centers on claim construction of “filament” and alleged anticipation/obviousness over prior‑art references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The USPTO granted institution of IPR2025-01562 filed by Imperative Care against Inari Medical's patent 11865291. The Board found the petitioner had a reasonable likelihood of prevailing on at least one claim, allowing the case to move forward.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that all nine claims of Inari Medical’s hemostasis valve patent are unpatentable. The Board’s claim construction of “filament” as a flexible element undermined the anticipation argument and found the obviousness combinations persuasive.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care successfully challenged the patentability of Inari Medical's hemostasis valve claims before the PTAB, leading to institution on grounds of anticipation and obviousness. The Board focused heavily on claim construction, ultimately defining 'filament' as a flexible length of material necessary for the device function. This decision sets important precedent regarding functional limitations in medical device patents.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that all nine claims of Inari Medical’s hemostasis‑valve patent are unpatentable, finding anticipation and obviousness over Schaffer and its combinations with Hartley, Eller, and Garrison.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s U.S. Patent 12,016,580 covering intravascular embolism treatment devices after finding Imperative Care’s obviousness arguments sufficiently promising.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB granted institution of an IPR against Inari Medical’s 12,016,580 hemostasis valve patent, finding a reasonable likelihood that Imperative Care will prevail on at least one of the nine challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s hemostasis valve patent after finding Imperative Care’s likelihood of success sufficient. All nine claims are now under trial.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care has filed an IPR petition seeking to invalidate Inari Medical’s 12,016,580 clot‑removal patent. The petition relies on Garrison and several other catheter‑related references to argue anticipation and obviousness under §§102 and 103. The Board has yet to decide whether to institute the review.
Samsung Electronics Co., Ltd. et al. v.Netlist, Inc.
The PTAB initiated a sua sponte Director Review of an IPR involving Sinclair Pharma and others versus Hydrafacial, staying the proceeding after the ITC affirmed the claims’ validity and commercial success.
Aesthetic Management Partners, LLC et al. v.HydraFacial LLC
Aesthetic Management Partners has filed an IPR petition seeking cancellation of all 20 claims of HydraFacial’s ’477 skin‑treatment patent. The petition relies on obviousness grounds under §103, citing multiple prior‑art references covering microdermabrasion and fluid delivery systems.
Aesthetic Management Partners, LLC et al. v.HydraFacial LLC
The USPTO granted institution for IPR2025-01217, allowing the trial to proceed after determining the petitioner had a reasonable likelihood of prevailing. This decision is part of a larger set of institutional rulings.
Ascentcare Dental Products, Inc. v.Solmetex, LLC
Ascentcare Dental Products has petitioned the PTAB to invalidate claims 1‑4 and 7‑18 of Solmetex’s 11,589,970 patent, alleging obviousness over several prior‑art dental mouthpiece references. The petition seeks institution of an IPR and cancellation of the challenged claims.
Ascentcare Dental Products, Inc. v.Solmetex, LLC
Ascentcare Dental Products has filed an IPR petition challenging Solmetex’s intraoral device patent, asserting that all claims 12‑21 are obvious over prior art. The petition relies on Park, Baughan, Johnson and Hirsch references and seeks cancellation of the claims.
Ascentcare Dental Products, Inc. v.Solmetex, LLC
Ascentcare Dental Products petitions the PTAB to invalidate Solmetex’s 11,589,969 intraoral mesh patent. The petition alleges anticipation and obviousness over five prior‑art references covering all independent and dependent claims.
Aerin Medical Inc. v.Neurent Medical Ltd. et al.
Aerin Medical has petitioned the PTAB to invalidate claims 1‑30 of Neurent’s ’973 patent, arguing obviousness over Townley and Wolf‑003/Wolf‑290 disclosures. The petition seeks institution and cancellation of the claims.
Ascentcare Dental Products, Inc. v.Solmetex, LLC
Ascentcare Dental Products has petitioned the PTAB to invalidate Solmetex’s 11,589,970 dental mouthpiece patent, asserting that all challenged claims are obvious over prior‑art references such as Park, Baughan, Johnson, Black and Hirsch.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.